Introduction
The Cited (CBP/p300-interacting transactivators with glutamic acid (E)/aspartic acid (D)-rich C-terminal domain) gene family consists of four nuclear proteins -Cited1 (formerly MSG1) (Shioda et al., 1996 (Shioda et al., , 1997 Dunwoodie et al., 1998) , Cited2 (formerly MRG1/ p35srj) (Shioda et al., 1997; Dunwoodie et al., 1998; Sun et al., 1998; Bhattacharya et al., 1999; Leung et al., 1999) , Cited3 (Andrews et al., 2000) , and Cited4 (formerly MRG2) (Braganca et al., 2002) . Members of this family function as transcriptional co-activators without classical DNA-binding domains. Cited2 interacts with the LIM domain of Lhx2 to enhance Lhx2-dependent transcription of LH/FSH glycoprotein a-subunit genes (Glenn and Maurer, 1999) . Cited2 and Cited4 interact with TFAP2, thereby activating TFAP2-mediated transcription (Braganca et al., 2002 . Transcriptional responses by Cited2 can be enhanced through its association with nuclear receptors, such as peroxisome proliferator activated receptor (PPAR), to enhance transcription of target genes (Tien et al., 2004) . Cited2 expression is induced by many cytokines and biological stimuli, including IL-1a, -2, -4, -6, -9 and -11, granulocyte/macrophage colony-stimulating factor, interferon-g, platelet-derived growth factor, insulin, serum, lipopolysaccharide, and hypoxia in diverse cell types (Sun et al., 1998; Bhattacharya et al., 1999) .
Cited2 has been proposed to play an important function in regulating the cellular responses to hypoxia. This is supported by the observation that hypoxia induces Cited2 expression. Elevated level of Cited2 then functions to downregulate hypoxia inducible factor (HIF)-1-driven transcription by competing with HIF-1a for binding to CBP/p300 Yin et al., 2002; Freedman et al., 2003) . We and others have shown that disruption of the gene encoding Cited2 is embryonic lethal and causes defects in the development of heart and neural tube (Bamforth et al., 2001; Barbera et al., 2002; Yin et al., 2002) .
Transforming growth factor (TGF)-bs are a highly conserved 25 kDa family of multifunctional autocrine, paracrine, and endocrine regulators that signal through interaction with cell surface receptors (Attisano and Wrana, 2000; ten Dijke et al., 2000) . Ligand-activated TGF-b receptors associate with and phosphorylate Smads 2 and 3, leading to nuclear translocation of these transcription factors, which serve as key intracellular mediators of TGF-b signaling (Attisano and Wrana, 2000; ten Dijke and Hill, 2004) . Receptor-activated Smad2 and Smad3 form hetero-complexes with Smad4, a common partner in the assembly of transcriptional complexes. These complexes are translocated into the nucleus and interact with a variety of transcription factors, such as AP-1, Sp1, FAST, ATF-3, TFE-3, nuclear receptors and E2F4/5, leading to activation or suppression of transcription (ten Dijke et al., 2000; Zimmerman and Padgett, 2000; Shi and Massague, 2003) . In addition to DNA-binding transcription factors, the co-activator function of CBP/p300 is essential for Smad-mediated transcription Janknecht et al., 1998; Nishihara et al., 1998; Topper et al., 1998) . The profile of Smad-binding cofactors during development or under various growth conditions determines cellular responses to TGF-b (Massague, 2000) .
Cited1 interacts with Smad4 and enhances Smad4-mediated transcription in reporter assays (Shioda et al., 1998; Yahata et al., 2000) . Cited1 is downregulated by TGF-b in melanoma cells (Shioda et al., 1998) . Recently, gene expression microarray analysis revealed that Cited2 is regulated by TGF-b in a variety of cell lines (Chen et al., 2001; Kang et al., 2003; Luo et al., 2005) . These studies suggest that Cited2 may play a role in modulating the TGF-b signaling network. To understand the function of Cited2 in TGF-b-mediated signaling pathway and target gene expression, we performed microarray analysis of gene expression modulated by TGF-b in mouse embryo fibroblasts (MEFs) following inducible expression of Cited2, and found that Cited2 effectively regulates responses of TGF-b on matrix metalloproteinase 9 (MMP9) expression. By knocking down Cited2 in MDA-MB-231 cells, we further discovered that Cited2 modulates TGF-bmediated expression of MMP9 and may play an important role in tumorigenesis.
Results

Cited2 is a co-activator for Smad3
Cellular responses to TGF-b are largely mediated by Smads, which serve as both transcription factors and transcriptional co-regulators. Much of the function of Smads is either mediated or modulated through association with a number of other transcription factors such as junB, ATF-3, and SnoN, whose expression may also be regulated by TGF-b (Jonk et al., 1998; Stroschein et al., 1999; Kang et al., 2003) . In line with those observations, TGF-b controls the expression of Cited2, as demonstrated in MDA-MB-231 and MCF-10A cells (Chen et al., 2001) . Cited1, another member of Cited family, is a Smad4 co-activator (Shioda et al., 1998; Yahata et al., 2000) . We thus investigated the role Cited2 may play in TGF-b signaling pathway. MDA-MB-231 cells were co-transfected with Smad3 and/or Cited2 plus SBE4-Luc, a TGF-b responsive reporter with four Smad-binding elements (SBE) in the promoter region to which Smad3 binds. Smad3 increased SBE4-Luc activity without stimulation of TGF-b (Figure 1 ), consistent with other reports. Co-transfection of cells with Cited2 further enhanced Smad3-mediated transcription, although Cited2 alone had no effect on SBE4-Luc activity (Figure 1 ). In the presence of TGF-b, activated endogenous receptor Smads translocate to the nucleus and bind SBE, thereby activating transcription of SBE4-Luc reporter. Cited2 alone enhanced TGF-bdependent activation of SBE4-Luc reporter, implying that activated endogenous receptor Smads may mediate this response. Consistent with this notion, under TGF-b stimulation, Smad3-mediated transcription was further enhanced in the presence of Cited2 (Figure 1 ). These experiments suggest that Cited2 could function as a coactivator to enhance Smad3-mediated transcription.
Cited2 interacts with Smads 2 and 3
We tested whether Cited2 enhances Smad3-mediated transcription by interacting with Smads, using a mammalian two-hybrid system. Gal4-Smad3 fusion protein mediated transcription of Gal4-binding site containing reporters, which was further enhanced by the coexpression of VP16 fused Cited2 (Cited2/VP16) ( Figure 2a ). These data suggest that Cited2 interacts with Smad3. We constructed Cited2 truncation mutants to map the Smad3-interacting region in Cited2. There are three conserved regions (CR) among different members of the Cited family (Figure 2b ). Construct aa.1-199 of Cited2/VP16, which includes the CR1 and CR3, but not CR2 domain of Cited2, did not interact with Gal4-Smad3 (Figure 2c ). In contrast, construct aa.124-269 of Cited2/VP16 containing the CR2, but not CR1 and CR3 domain of Cited2, interacted with Gal4-Smad3 (Figure 2c ), suggesting that the C-terminal region of Cited2 is essential for the interaction with Smad3. Equivalent expression levels of various Cited2 constructs were detected in Figure 2c .
To further confirm the interaction between Cited2 and Smad3, glutathione S-transferase (GST) pull-down assay was performed. Full-length Cited2 and Cited2 mutant without the C-terminal region were in vitro Figure 1 Cited2 enhances Smad3-mediated transactivation. 1 Â 10 5 MDA-MB-231 cells were plated and transfected with 300 ng of pSBE4-Luc together with 300 ng of pRK5-Flag-Smad3, pcDNA3.1-Cited2, or both. At 24 h after transfection, cells were treated with or without 2.5 ng/ml of TGF-b for another 24 h, followed by luciferase assay. Results are representative of three individual experiments. *Po0.05 comparing the indicated two bars.
þ Po0.05 comparing the indicated two bars.
Cited2 is a transcriptional modulator in TGF-b signaling pathway Y-T Chou et al Figure 2 Cited2 interacts with Smad2 and Smad3. (a) 4 Â 10 4 HEK293T cells were co-transfected with 100 ng of MH100 reporter (Gal4 responsive luciferase reporter), pM-Smad3 (Gal4-Smad3), pVP16-HA1 vector containing full-length Cited2 in-frame with VP16-HA1 (Cited2/VP16), and empty pVP16-HA1 vector (100 ng each) in different combination for 48 h, followed by luciferase assay. (b) Schematic representation of Cited2 shows different domains of Cited2 and the deletion constructs used in the experiment. Abbreviation CR represents the conserved region among different members of the Cited family. (c) 4 Â 10 4 HEK293T cells were co-transfected with MH100 reporter (100 ng), pM-Smad3 (100 ng), and pVP16-HA1 vector containing different portions of Cited2 (100 ng each) for 48 h, followed by luciferase assay. *Po0.01 comparing to VP16 alone. Cell lystes transfected with different Cited2 deletion VP16-HA fusion construct were subjected to Western blot analysis with antibodies against HA. (d) (Left) Equal volumes of glutathione S-transferase (GST) and GST-Smad3 bound to glutathione sepharose were mixed with in vitro transcribed and translated Myc-tagged wild-type Cited2 (WT) (aa 1-269) and Cited2 mutant (aa1-199). Glutathione S-transferase-pull-down assay was performed as described in Materials and methods. In all, 50% input and pull-down products were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and detected by Western blot analysis with antibodies specific for Myc. (Right) Equal volumes of GST and GST-Cited2 bound to glutathione sepharose were mixed with in vitro transcribed and translated wild type Myc-tagged Smad3 (WT) (aa 1-425) and Myc-tagged Smad3 mutant without MH2 domain (MH2) (aa 1-225). In all, 50% input and pull-down products were separated by SDS-PAGE and detected by Western blot analysis with antibodies specific for Myc. (e) Top panel shows the binding of Myc-tagged full-length Cited2 to GST-Smad2, GST-Smad3 and GST-Smad4. A total of 50% input and pull-down products were separated by SDS-PAGE and detected by Western blot analysis with antibodies specific for Myc. Bottom panel is Coomassie blue-stained gel showing relative amounts of GST, GST-Smad2, transcribed and translated ( Figure 2d ). As shown in Figure 2d , wild-type Cited2, but not Cited2 C-terminal deletion mutant (Cited2 aa.1-199), interacted with GSTSmad3, which further confirms that the C-terminal region of Cited2 is necessary for interaction with Smad3. As the MH2 domain of Smad3 is responsible for interaction with various transcription factors, we tested whether Cited2 interacts with Smad3 mutant (Smad3 aa.1-225), which contains the MH1 domain and the linker region but not the MH2 domain of Smad3. In vitro transcribed/translated full-length Smad3, but not Smad3 mutant lacking the MH2 domain, interacted with GST-Cited2 (Figure 2d ), supporting that MH2 domain of Smad3 interacts with Cited2. We tested whether other Smads interact with Cited2. As shown in Figure 2e , Cited2 interacted with GST-Smad2 and GSTSmad3, but not GST-Smad4 fusion protein. These experiments support our hypothesis that Cited2 interacts with Smads 2 and 3.
Cited2 promotes Smad3/p300-mediated transcription Transcriptional co-activator p300 interacts with Smad3 and Cited2 through the C-terminus and the CH1 domain of p300, respectively (Nishihara et al., 1998 (Nishihara et al., , 1999 Bhattacharya et al., 1999) . We thus speculated that p300 may modulate the interaction between Cited2 and Smad3. As p300 interacts with only the phosphorylated Smad3 (Shen et al., 1998) , we co-transfected constitutively activated form of TGF-b receptor 1 (ALK5*) with Smad3, Cited2, and/or p300 in HEK293T cells. Co-transfection with p300 increased the level of Cited2 co-immunoprecipitated with Flag-tagged Smad3 (Figure 3a) , indicating that p300 enhances the interaction between Cited2 and Smad3. It has been shown that p300 is important for Smad-mediated transcription Janknecht et al., 1998; Nishihara et al., 1998; Topper et al., 1998) . Transfection of HEK293T cells with p300 alone modestly enhanced Smad3-mediated transcription of SBE4-Luc (Figure 3b ). However, co-transfection of both Cited2 and p300 significantly promoted Smad3-mediated transcription of SBE4-Luc (Figure 3b) .
We further asked whether p300 or Cited2 enhances Gal4-Smad3-mediated transcription by tethering Smad3 to Gal4 DNA-binding domain. Interestingly, co-transfection of cells with both p300 and Cited2 significantly enhanced Gal4-Smad3-mediated transcription even in the absence of TGF-b (Figure 3c ). In contrast, cotransfection of cells with p300 and a Cited2 mutant encoding aa.1-199 did not enhance Smad3-mediated transcription (Figure 3c ). These data support the conclusion that Cited2 enhances Smad3/p300-mediated transcription.
Cited2 enhances TGF-b-mediated expression of MMP9
In order to understand the function of Cited2 in TGF-b signaling, we adopted a novel approach by manipulating tetracycline-controlled expression of Cited2 in Cited2-null MEFs, followed by microarray analysis to search for TGF-b responsive genes regulated by Cited2.
Cited2
À/À MEF cells were immortalized with retrovirus expressing SV40 large T antigen (LT), followed by stable transfection of a tet-off vector (pBPSTR1) containing the Cited2 coding sequence to generate Cited2
. Cited2 mRNA and protein were not expressed in tetracycline-treated Cited2 (Figure 5d ). These data support the conclusion that the Smad pathway is involved in TGF-b-mediated upregulation of MMP9, a target gene for Cited2, in MDA-MB-231 cells.
Cited2 enhances TGF-b-mediated MMP9 promoter reporter activity
To localize TGF-b responsive region in the MMP9 promoter, we designed a series of MMP9 promoterluciferase reporter constructs, with point mutations or deletions, which were then used to study regulation of transcriptional control of MMP9 by TGF-b in MDA-MB-231 cells. Deletions upstream of À151 bp in the MMP9 promoter region maintained TGF-bmediated response (Figure 6a ). The proximal (À73/ À79) AP-1 site (TGAGTCA) is well conserved among human, rat, and mouse MMP9 promoters, and has high sequence homology to the TGF-b responsive elements, TGACTCA and TGAGTTCA, in human MMP13 and rat PAI-1 promoters, respectively (Uria et al., 1998; Guo et al., 2005) . Given that both proximal AP-1 and NF-kB cis-elements are essential for mitogeninduced MMP9 upregulation (Ma et al., 2004) , proximal AP-1 and NFkB mutants of MMP9 promoter were further tested for TGF-b-mediated response. Matrix metalloproteinase 9 promoter with a specific mutation in À/À (LT þ , pBPSTR1-Cited2), were generated by retroviral infection of Cited2 À/À MEFs with pBPSTR1-Cited2. Tetracycline-mediated downregulation of Cited2 was monitored by Western blot analysis using anti-Cited2 antibody.
MEFs from (a) were cultured with or without tetracycline for 24 h, followed by adding 2.5 ng/ml of TGF-b or reconstitution buffer to the media for another 4 h. Total RNA was isolated and subjected to Northern analysis with specific probes for Cited2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (c) Total RNA from (b) was subjected to real-time PCR with specific primers for mouse MMP9 and normalized with mouse b-actin. *Po0.01 comparing ÀTet (Cited2 on) to þ Tet (Cited2 off) in the presence of TGF-b.
MEFs were treated with tetracycline for 24 h, followed by stimulation with 2.5 ng/ml of TGF-b for another 24 h in absence of serum. The serum-free conditioned media were collected and condensed with centricon 3, followed by Western blot analysis with specific antibodies against MMP9. The relative intensity of specific bands was quantified with densitometry. (e) Cited2 À/À (LT þ , pBPSTR1-Cited2) MEFs were treated with tetracycline for 24 h, followed by stimulation with 2.5 ng/ml of TGF-b for another 24 h in the absence or presence of serum. The conditioned media were collected, followed by gelatin zymographic assay. (f) MCF-10A, MDA-MB-231, and MCF-7 cells were treated with or without 2.5 ng/ml of TGF-b for 4 h. Total RNA was isolated, followed by Northern analysis with specific probes for Cited2 and GAPDH. (g) MDA-MB-231 cells were transfected with si-Cited2 (lane 3, 4) or si-Control (lane 5, 6; negative control) for 60 h, followed by TGF-b stimulation for another 4 h (lane 2, 4, 6). Total RNA was extracted by Trizol, and Northern analysis was performed. (h) MDA-MB-231 cells were transfected with si-Cited2 or si-Control for 60 h, followed by TGF-b stimulation for another 24 h. Total RNA was extracted, followed by quantitative real time PCR with specific primers for human MMP9 and normalized with human GAPDH. (i) The RT-PCR products of RNA samples from (h) were loaded onto a 12% polyacrylamide gel to demonstrate the relative mRNA levels of MMP9, Cited2, and GAPDH. (j) Serum-free conditioned media from (h) were collected and subjected to gelatin zymographic assay. Results are representative of four individual experiments. the proximal AP-1 site not only decreased the basal level expression but also abolished TGF-b-mediated upregulation of MMP9 transcription (Figure 6a ). Co-transfection of Cited2 was able to enhance TGF-bmediated expression of wild-type but not MMP9 promoter mutated at the AP-1 site (Figure 6b ). Smad7 and dominant negative Smad4 have been shown to inhibit Smad pathway by interfering with phosphorylation and translocation of endogenous Smads, respectively (Hayashi et al., 1997; Zhang et al., 1997) . Coexpression of Smad7 or dominant negative Smad4 attenuated Cited2-mediated expression of MMP9 promoter reporter, suggesting that endogenous Smads are required for functional interaction with Cited2 to enhance MMP9 expression (Figure 6b ). These data further confirm that Cited2 functions as a co-activator to enhance TGF-b-mediated upregulation of MMP9.
Transforming growth factor-b regulates MMP9 expression by recruiting Cited2 and Smad3 to the MMP9 promoter Our findings suggest that Cited2 enhances TGF-bmediated expression of MMP9. To further understand how Cited2 regulates the expression of endogenous genes upon TGF-b stimulation, we performed real-time polymerase chain reaction (PCR) to monitor the expression of MMP9 and Cited2 mRNA (Figure 7a) . During the first 4 h of TGF-b stimulation, MMP9 mRNA expression was not significantly enhanced, whereas Cited2 was downregulated by TGF-b. Interestingly, as Cited2 mRNA expression started to resume at 12-24 h after stimulation, MMP9 expression was strongly enhanced (Figure 7a ). As it has been reported before that Smad3 is recruited to the MMP13 promoter upon TGF-b stimulation (Selvamurugan et al., 2004a , b), we tested whether Smads and Cited2 are recruited to the promoter region of MMP9. Chromatin immunoprecipitation with the MMP9 promoter was performed using antibodies against Cited2 and Smads. At 4 h after TGF-b stimulation, occupancy of Smad2/3 on MMP9 promoter was increased (Figure 7b ). Interestingly, 24 h after stimulation, occupancy of Cited2 was sharply increased on the MMP9 promoter (Figure 7b ), during which an increased Smad2/3 on the promoter was also observed. These data, therefore, would support our hypothesis that Cited2 functions as a transcriptional modulator of Smad2/3 by simultaneously binding to the (Figure 8b) . These experiments imply that by modulating the expression of MMP9, Cited2 could play a significant role during tumor invasion.
Discussion
Smads are key mediators in the TGF-b signaling pathway. Smad-binding cofactors determine the magnitude, duration, and direction (activation or suppression) of Smad-driven transcription during TGF-b stimulation (Attisano and Wrana, 2000; ten Dijke and Hill, 2004) . Transfection studies support that Cited1 functions as a Smad co-activator (Shioda et al., 1998; Yahata et al., 2000) . However, a direct demonstration that Cited1 regulates endogenous genes was never performed. In this study, we have provided evidence supporting that Cited2 interacts with Smad3 and functions as a Smad3 co-activator in TGF-b signaling. Cited2 is recruited to (Glenn and Maurer, 1999) , TFAP2 (Braganca et al., 2002; Braganca et al., 2003) , the nuclear receptor PPAR (Tien et al., 2004) , and HIF-1a Freedman et al., 2003; Fox et al., 2004) through interaction with CBP/p300. The role for CBP/p300 as an essential co-activator in Smad driven gene expression has been well documented by observations that overexpression of E1A antagonizes the function of CBP/ p300, which leads to attenuation of Smad-driven transcription Nishihara et al., 1998; Pouponnot et al., 1998; Topper et al., 1998) . However, coexpression of CBP/p300 has modest effects on Smadmediated transcription based on several promoter/ reporter assays Warner et al., 2004) . The effects of p300 on Smad-driven transcription may rely on the recruitment of other co-activators to the Smad/p300 complex (Dennler et al., 2005) . We show that p300 enhances the interaction between Cited2 and Smad3 (Figure 3a) . Coexpression of Cited2 and p300 Figure 6 Cited2 enhances the expression of matrix metalloproteinase 9 (MMP9) promoter reporter. (a) Schematic representation of mutant constructs in the human MMP9 promoter. The promoter was divided into (a-f) subregions. 5 Â 10 4 MDA-MB-231 cells were plated and transfected with 300 ng of various deletion constructs of MMP9 promoter reporters as indicated. At 24 h after transfection, cells were treated with or without 2.5 ng/ml of transforming growth factor (TGF)-b for another 24 h, followed by luciferase assay and normalized to sea pansy luciferase activity of co-transfected pRL-SV40. (b) 5 Â 10 4 MDA-MB-231 cells were plated and co-transfected with 300 ng of wild-type MMP9 (black bars) or AP-1 mutant (white bars) promoter reporter and together with pcDNA3.1-Cited2 (100 ng), Flag-CMV2-Smad7 (100 ng), and 100 ng of dominant negative Smad4 expression vector (DN-Smad4) in different combination. At 24 h after transfection, cells were treated with or without 2.5 ng/ml of TGF-b for another 24 h, followed by luciferase assay and normalized to sea pansy luciferase activity of co-transfected pRL-SV40. Results are representative of two independent experiments. *Po0.05 compared to wild-type MMP9 promoter in the presence of TGF-b. **Po0.05 compared to wild-type MMP9 promoter with Cited2 in the presence of TGF-b. Cited2 is a transcriptional modulator in TGF-b signaling pathway Y-T Chou et al enhances Smad3-mediated transcription (Figure 3b and c), which corroborates the notion that Cited proteins represent a novel family of transcription modulators to regulate the activities of various CBP/p300 complexes. It is interesting that overexpression of p300 without Cited2 and in the absence of TGF-b decreased Gal4-Smad3-mediated transcription (Figure 3c ). Without TGF-b receptor-mediated phosphorylation, wildtype Smad3 does not interact with p300 (Shen et al., 1998) . Overexpression of p300 may interact with other endogenous transcription factor complexes, such as Cited2 and TFAP2, to decrease the endogenous pool of free Cited2, and in turn affect Gal4-Smad3-mediated transcription. These data suggest other transcription factors including Cited2 are involved in Smad3/p300-mediated transcription.
Our microarray analysis with tet-off inducible Cited2 MEF and siRNA-mediated knockdown experiments in MDA-MB-231 cells show that Cited2 modulates TGF-b-mediated expression of MMP9. Matrix metalloproteinase 9 are matrix metalloproteinases capable of degrading extracellular matrix (ECM), and strict regulation of MMP synthesis is critical for the maintenance of proper ECM expression (Sternlicht and Werb, 2001) . In disease states such as cancer, there is often high MMP activity at the tumor-stroma interface (Lynch and Matrisian, 2002) . Excessive deposition of ECM has been detected in Engelbreth-Holm-Swarm (EHS) tumors and differentiated F9 embryonic carcinoma (F9-PE). Interestingly, Cited1 and Cited2 are highly expressed in EHS tumors and upregulated during the differentiation of F9-PE, suggesting that Cited1 and Cited2 may be involved in the regulation of ECM (Futaki et al., 2003) . Matrix metalloproteinase 9 is activated through both proteolytic and non-proteolytic mechanisms. Full-length MMP9 is the major form of MMP9 in cancer tissues (Fridman et al., 2003) and in MDA-MB-231, an invasive breast cancer cell line. Several studies have suggested that without the participation of proteolytic enzymes and removal of the inhibitory peptide, full-length MMP9 can be activated by binding to the substrates to cause conformational changes or oxidative modification of the cysteine sidechain thiol groups, in turn allowing zinc ion to become available for the catalytic function (Okamoto et al., 2001; Bannikov et al., 2002; Gu et al., 2002) . Transforming growth factor-b is a potent growth inhibitor of normal epithelial cells, but also fosters tumor formation during later stages of tumorigenesis (Wakefield and Roberts, 2002) . Transforming growth factor-b enhances the expression of MMP9, which plays significant roles during the dissemination and growth of cancer cells (Itoh et al., 1999; Coussens et al., 2000; Hiratsuka et al., 2002) .
Although Cited2 is a transforming gene, as we previously showed, and overexpression of Cited2 in Rat1 cells causes tumor formation in nude mice (Sun et al., 1998) , the mechanism involved in tumor formation was unclear. Our current demonstration that Cited2 modulates TGF-b-mediated upregulation of MMP9 and enhances in vitro tumor cell invasion may in part explain why overexpression of Cited2 promotes tumor formation in nude mice. In addition to MMP9, Cited2 also modulates MMP13 expression in MDA-MB-231 cells (Supplementary Information). Yokota et al. (2003) showed that, in a human chondrocyte cell line C-28/I2, MMP1 and MMP13 are downregulated by TGF-b, possibly through Cited2. In addition, they showed that Cited2 is upregulated by TGF-b (Yokota et al., 2003) , which is different from our study and those of others (Chen et al., 2001; Tardif et al., 2001; Kang et al., 2003; Luo et al., 2005) . These discrepancies could be owing to the use of different cell lines. Although Cited2 overexpression enhances TGF-b-mediated expression of MMP9 in Cited2 inducible MEFs, MMP9 upregulation by TGF-b is not totally abolished in the Cited2 null background, suggesting that other transcription factors or cofactors may also be involved in MMP9 upregulation by TGF-b.
Smad proteins are the main trans-acting factors involved in TGF-b-stimulated MMP13 expression in MDA-MB-231 cells (Selvamurugan et al., 2004a, b) . 
Cited2 is a transcriptional modulator in TGF-b signaling pathway Y-T Chou et al
It has been reported that the AP-1 site in the MMP13 promoter region is essential for TGF-b-stimulated MMP13 expression (Uria et al., 1998; Selvamurugan et al., 2004b) . Here, we demonstrated that mutation of the proximal AP-1 site in the MMP9 promoter abolishes TGF-b-mediated response. In addition to Smad-binding elements, Smads are recruited to the promoter through AP-1 complexes Yamamura et al., 2000) . Although Zhang et al. (1998) have showed that Smad3 directly binds to AP-1 sequences in MMP1 promoter, it is also suggested that Smad2/3 may interact with transcription factors, such as junB and Cbfa1/ runx2, rather than directly binding to the DNA for the MMP13 promoter activity (Selvamurugan et al., 2004 b) . Whether Smad3 and Cited2 directly bind to the MMP9 promoter or are recruited through other DNAbinding transcription factors requires further investigation. We have observed that more Cited2 are recruited to the MMP9 promoter in the absence of TGF-b than 4 h after stimulation. As Cited2 interacts with transcription factors such as TFAP2 and Lhx2 other than Smads, we do not rule out the possibility that in the absence of TGF-b, TFAP2 may also recruit Cited2 to the MMP9 promoter. TGF-b activates Smads 2 and 3 by rapid (i.e., 15 min) yet transient phosphorylation (Selvamurugan et al., 2004a, b) . It is difficult to reconcile that MMP9 and MMP13 expression stimulated by TGF-b does not significantly occur till 24 h following stimulation (Selvamurugan et al., 2002) . Our data here imply that Cited2 plays an essential role in regulating TGF-b-mediated MMP9 expression. Cited2 is recruited to the MMP9 promoter and the kinetics of Cited2 expression correlates with the mRNA levels of MMP9 during TGF-b stimulation. These data suggest that by modulating the expression of Cited2, TGF-b creates a temporal and specific control to regulate the expression of late TGF-b responsive genes such as MMP9. Several regulatory mechanisms that create temporal controls in TGF-b signaling network have been demonstrated. SnoN, a Smad-binding repressor, is rapidly degraded in response to TGF-b. At later stages of TGF-b stimulation, TGF-b induces SnoN expression, resulting in termination of Smad-mediated transactivation (Stroschein et al., 1999; Sun et al., 1999) . Smad7, an antagonistic Smad induced by TGF-b, interferes with the binding between Smad2/3 and TGF-b receptor, to attenuate TGF-b-mediated responses (Hayashi et al., 1997) . We also show that Cited2 is a Smad3/p300 co-activator, but is modulated by TGF-b in MDA-MB-231 cells. As Cited2 expression resumes at later time points of TGF-b stimulation, Cited2 enhances Smad2/3-mediated upregulation of MMP9. Interestingly, Cited1, another member of the Cited family and a Smad4-interacting co-activator, is also downregulated by TGF-b in B16-F1 melanoma (Shioda et al., 1998) . Whether such a temporal control identified in this study reflects a unique property also shared by other Cited family members to modulate TGF-b responses will require further investigation.
In conclusion, the present data provide strong evidence for the involvement of Cited2 in TGF-b signaling. Cited2 functions as a Smad2/3-binding coactivator and is important for Smad3/p300-mediated transcription. In MEFs and MDA-MB-231 cells, Cited2 modulates TGF-b-mediated upregulation of MMP9. Knockdown of Cited2 in MDA-MB-231 cells attenuates TGF-b-mediated invasion of MDA-MB-231 cells. Unraveling the role of Cited2, a novel modulator in TGF-b signaling, could contribute to the understanding of effects of TGF-b signaling on development and tumorigenesis.
Materials and methods
Reagents and antibodies
Recombinant human TGF-b1 was purchased from R&D Systems (Minneapolis, MN, USA). Tetracycline and puromycin were obtained from Sigma (St Louis, MO, USA). Anti-MMP9 antibodies were ordered from Chemicon, Temeculo, CA, USA. Anti-Myc (A14), anti-Smad1/2/3 (SC7960), antiCited2 (MRG1, JA22) antibodies, and normal IgG1 (SC3877) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Flag (M2) and anti-b-actin antibodies were obtained from Sigma (St Louis, MO, USA). Anti-MMP13 (Ab-4) antibodies were purchased from Calbiochem (San Diego, CA, USA).
Cell culture MDA-MB-231 and MCF-7 cells were obtained from the American Type Culture Collection. MCF-10A was provided by Dr Amy Wilson-Delfosse (Case Western Reserve University). Primary MEF cultures were harvested and maintained as described (Yin et al., 2002) . For generation of MEF cell lines, primary MEFs were immortalized by retroviral infection with a retroviral vector containing simian virus 40 LT antigen (Williams et al., 1988) , provided by Dr David Williams (University of Cincinnati). Inducible Cited2 MEFs, Cited2
, were generated from a SV40 LTimmortalized Cited2 À/À MEF line infected with the pBPSTR1 vector containing Cited2 cDNA. Mouse embryo fibroblasts and HEK293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Logon, UT, USA). MDA-MB-231 and MCF-7 cells were maintained in minimum essential medium supplemented with 1 nM insulin (Sigma) and 10% heat-inactivated FBS. MCF-10A cells were maintained in a 1:1 mixture of DMEM and Ham's F-12 supplemented with 25% horse serum (Invitrogen, Auckland, New Zealand), 10 mg/ml insulin, 0.5 mg/ml hydrocortisone (Sigma), and 20 ng/ml epidermal growth factor (Sigma).
Plasmids
Mouse Cited2 was cloned from mouse genomic DNA, followed by subcloning into pcDNA3.1(À)B, pM, pVP-HA1, and PGEX4T1. pM was purchased from CLONTECH, Palo Alto, CA, USA and pVP16-HA1 was provided by Dr Richard Baer (University of Texas Southwestern Medical Center). pM was used to generate a fusion protein with the Gal4-DNAbinding domain. MH100, a Gal4 responsive luciferase reporter, was provided by Dr Hung-Ying Kao (Case Western Reserve University). Cited2 deletion mutants were PCR amplified and cloned into pVP16-HA1 and pcDNA3.1(À)B. Rat Smad3 was subcloned into pM and pcDNA3.1(À)B. Rat Smad3 mutant lacking MH2 domain was PCR amplified and subcloned into pcDNA3.1(À)B. pRK5-Flag-Smad3 is a gift from Dr Rick Derynck (University of California, San Francisco). pSBE4-Luc was a gift from Dr Bert Vogelstein (Johns Hopkins University). ALK5*(T204D) and dominant negative Smad4/DPC4(1-514) were provided by Dr Joan Massague (Memorial Sloan-Kettering Cancer Center). pBPSTR1 was obtained from Dr Steven Reeves (Harvard University). Flag-tagged Smad7 with a consensus Kozak sequence was PCR amplified from Flag-CMV2 vector and subcloned into pBABE-puro. A series of deletion mutants of the human MMP9 promoter reporter constructs were made and described previously (Ogawa et al., 2004) . Wild-type, NF-kB, and AP-1 mutant of MMP9 promoter reporter were kind gifts from Dr Hiroshi Sato (Cancer Research Institute, Kanazawa University, Kanazawa, Japan) (Sato and Seiki, 1993) .
Luciferase assay, DNA transfection, and siRNA For luciferase assays, MDA-MB-231 cells were transfected using Lipofectamine Plus reagent (Invitrogen) following the manufacturer's instructions. HEK293T cells were transfected by the calcium phosphate method. Luciferase activity in cell lysates was determined by a dual luciferase reporter assay system (Promega, Madison, WI, USA) and normalized to sea pansy luciferase activity of co-transfected pRL-CMV or pRL-SV40. Statistical significance was determined by Student's t-test. For siRNA knockdown experiment, MDA-MB-231 cells were transfected with siRNA using Effectene transfection reagent (Qiagen, Hilden, Germany) for 60 h following the manufacturer's instructions. siRNAs for Cited2 and ZNF76 (a negative control) were ordered from Dharmacon Research (Lafayette, CO, USA). The siRNA sequence for Cited2 is 5 0 -ugacggacuucgugugcaa-3 0 and for ZNF76 5 0 -ccagcgccaccaa cuauaa-3 0 . The reconstitution of siRNA was performed following the manufacturer's instructions.
Purification of GST fusions, in vitro transcription/translation, and GST pull-down assay Purification of GST-fusion proteins and GST pull-down assay have been described previously (Chipuk et al., 2002) . Briefly, cDNA from wild type of Cited2 (aa1-269), Cited2 C-terminal deletion mutant (aa 1-199), wild type of Smad3 (aa1-425), and Smad3 deletion mutant (aa 1-225) were subcloned into pcDNA3.1(À)B and in vitro transcribed and translated using TNT Coupled Reticulocyte Lysate Systems (Promega). Glutathione S-transferase fusion proteins were immobilized on Glutathion-sepharose beads first. In vitro transcribed and translated peptides were incubated with 10 mg of GST-fusion protein in phosphate-buffered saline (PBS) supplemented with 0.1% Triton X-100 and rotated overnight at 41C. The beads were washed with the PBS/0.1% Triton X-100 buffer three times and resuspended in 50 ml of 2 Â sodium dodecyl sulfate (SDS) sample buffer. The pull-down products were heated at 951C for 5 min and applied to SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Retrovirus infection pBPSTR1-Cited2 was generated by inserting Cited2 cDNA into multiple cloning sites of pBPSTR1, a retroviral tet-off vector. pBABE-Smad7 was generated by inserting Smad7 cDNA into multiple cloning sites of pBABE-puro, a retrovirus vector. Phoenix packaging cells were used to generate amphotropic retroviruses. Briefly, Phoenix cells were seeded at a density of 3.5 Â 10 6 cells per 10-cm dish, and transfected with 10 mg of retrovirus vector by the calcium phosphate method the following day. At 48 h after transfection, virus-containing supernatant was collected. For generation of tet-off inducible Cited2 MEF lines, a Cited2 À/À MEF line infected with retrovirus expressing Cited2 was selected with 2.5 mg/ml of puromycin for 1 week. Individual clones were picked and Cited2 protein and mRNA expression levels were monitored 24 h after culturing cells in 2 mg/ml of tetracycline. For generation of Smad7-overexpression cells, MDA-MB-231 cells were infected with retrovirus expressing Flag-tagged Smad7, followed by puromycin selection for 1 week. In order to avoid clonal variations, pools of transfectants expressing Smad7 or vector alone were used and subjected to analysis after puromycin selection and Western blot confirmation.
Western blot analysis Cells were lysed into radioimmunoprecipitation assay buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin, and 20 mg/ml leupeptin). Lysates were fractionated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (PVDF-plus; Osmonics Inc., Westborough, MA, USA). Membranes were incubated with primary antibodies followed by incubation with secondary antibodies conjugated to horseradish peroxidase. Reacted secondary antibodies were detected using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Northern blot analysis
Total RNA was isolated from cells using Trizol reagent (Invitrogen) following the manufacturer's instructions. In total, 10 mg per lane of total RNA was separated by 2.2 M formaldehyde agarose gel electrophoresis, and transferred to a nylon membrane (Magna; Osmonics Inc.). . Total RNA was isolated by the Trizol (Invitrogen) method and reverse transcribed using the SuperScriptt First-Strand Synthesis System for RT-PCR (Invitrogen). Real time PCR was performed with iQt SYBER-Green Supermix (Bio-Rad, Hercules, CA, USA) in a MyiQ thermocycler (Bio-Rad) using a SyBr Greent detection protocol as outlined by the manufacturer. Quantitations were normalized to endogenous GAPDH or b-actin. The relative quantitation value for each target gene compared to the calibrator for that target is expressed as 2 ÀðCtÀCcÞ (C t and C c are the mean threshold cycle differences after normalizing to GAPDH or b-actin).
SYBER-Green real-time PCR
Zymographic assay Cited2
À/À (LT þ , pBPSTR1-Cited2) MEFs treated with tetracycline, or MDA-MB-231 cells transfected with siRNA, were stimulated with or without TGF-b. After 24 h, the conditioned media were collected and mixed with Â 5 loading buffer (4% SDS, 20% glycerol, 0.01% bromophenol blue, and 125 mM Tris-HCl, pH 6.8). The samples were subjected to 7.5% SDS-PAGE containing 2 mg/ml gelatin (Sigma). After electrophoresis, the gel was washed three times with 2.5% Triton X-100, briefly with distilled water, and incubated with reaction buffer (50 mM Tris-HCl, pH 7.5, 10 mM CaCl 2 , 1 mM ZnCl 2 , 150 mM NaCl, 1% Triton X-100, and 0.002% sodium azide) for 16 h at 371C. The gel was stained with 0.25% Coomassie Brilliant Blue R-250 and destained with 40% methanol, 10% acetic acid as previously described (Heussen and Dowdle, 1980) .
Microarray measurement Cited2
À/À (LT þ , pBPSTR1-Cited2) MEFs were incubated with medium containing 2 mg/ml tetracycline or solvent for 24 h, followed by stimulation with 2.5 ng/ml TGF-b or reconstitution buffer for another 4 h. Total RNA was extracted by Trizol and high-density oligodeoxynucleotide microarray analysis was performed in the Gene Expression Analysis Core Facility of Case Western Reserve University.
Chromatin immunoprecipitation (ChIP) Cells were incubated for 10 min at 371C with medium containing 1% formaldehyde. Formaldehyde crosslinking was stopped by adding glycine to a final concentration of 125 mM for 5 min at 371C. Cells were then washed with ice-cold PBS containing protease inhibitors and 1 mM phenylmethylsulfonyl fluoride and resuspended in SDS lysis buffer containing protease inhibitors for 5 min on ice. Samples were sonicated to reduce the DNA length to 200-600 bp, cellular debris was removed by centrifugation, and the supernatant was diluted 20-fold in dilution buffer supplemented with protease inhibitors. Before ChIP, the samples were precleared with protein A-agarose/carrier DNA/tRNA mixture. The supernatant was recovered and used directly for immunoprecipitation experiments by incubation with appropriate antibodies overnight at 41C. Immune complexes were mixed with protein A-agarose/carrier DNA/tRNA mixture followed by incubation for 1 h at 41C. After immunoprecipitation, beads were collected and sequentially washed twice with 1 ml each of the following buffers: low-salt wash buffer, high-salt wash buffer, LiCl wash buffer, and TE buffer. The immunocomplexes were eluted twice by adding a 250 ml aliquot of a freshly prepared solution of 1% SDS/0.1 M NaHCO 3 . Then, 20 ml of 5 M NaCl and 1 ml of 10 mg/ml RNase were added to the samples and the crosslinking reaction was reversed by 6 h incubation at 651C. The samples were then digested with proteinase K at 421C for 1 h, and DNA was recovered by phenol/chloroform extraction and precipitated with two volumes of ethanol and 5 ml of 10 mg/ml glycogen. The input lysates were processed as above. DNA was resuspended in water and analysed by quantitative real-time PCR. The primer sequences of the human MMP9 promoter used are: 5 0 -agagaggaggaggtggtgtaagc-3 0 and 5 0 -ttggtgagggcagaggtgtc-3 0 .
[ 3 H]thymidine incorporation assay MDA-MB-231 cells were transfected with siRNA. After 60 h, cells were washed with PBS and plated into 12-well plates at a density of 2 Â 10 4 cells per well. The following day, cells were stimulated with or without 2.5 ng/ml of TGF-b for 33 h. Cells were labeled with 4 mCi of [ 3 H]thymidine for 3 h and fixed with 10% trichloroacetic acid (TCA) for 30 min at 251C, followed by two washes with 10% TCA. DNA was solubilized by incubation in 500 ml of 0.2 N NaOH for 30 min, and radioactivity was counted using 400 ml of solubilized DNA in 4 ml scintillation fluid.
Matrigel invasion assay
Invasion through BM Matrigel was performed as previously described with minor modifications (Melchiori et al., 1987) . MDA-MB-231 cells were transfected with siRNA. After 60 h, cells were stimulated with or without 2.5 ng/ml of TGF-b for another 24 h. Cells were detached and resuspended in mimimum essential medium (MEM) containing 0.1% BSA with antibiotics, with or without TGF-b in the absence of serum. A total of 1 Â 10 5 cells were added to the upper well of a 24-well matrigel invasion chamber (BD Biosciences, Bedford, MA, USA) and incubated at 371C for 20 h. The lower chamber contained MEM with 5% FBS. Cells that traversed through the filter were fixed, stained with 0.5% (w/v) crystal violet and counted in five random fields per insert. Each assay was repeated five times and performed in triplicate.
